MoonLake Immunotherapeutics (MLTX)
NCM · Healthcare · Biotechnology
$18.69
+5.30%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$1.38B
Shares Outstanding
73.6M
Exchange
NCM
Currency
USD
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -60.7M | -71.4M | -65.2M | -70.0M |
| Net Income | -55.2M | -69.7M | -62.4M | -69.7M |
| Diluted EPS | $-0.87 | $-1.10 | $nan | $-0.98 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -65.1M | -54.1M | -143.1M | -244.8M |
| Net Income | -50.0M | -36.0M | -118.9M | -227.3M |
| Diluted EPS | $-1.28 | $-0.73 | $-1.89 | $-3.53 |